POTOMAC, MARYLAND — February 9, 2026 — Leads & Copy — IGC Pharma, Inc. (NYSE American:IGC) has expanded its Phase 2 CALMA trial for IGC-AD1 into Colombia, South America, through the addition of Grupo de Neurociencias de Antioquia (GNA).
This expansion marks a pivotal operational milestone as IGC enters a region internationally recognized for its unique, genetically linked Alzheimer’s population. The GNA site is the latest addition to a clinical network that now spans 23 active sites across 26 locations in the United States and Canada.
CALMA is a randomized, double-blind, placebo-controlled Phase 2 study that has now reached approximately 70% of planned enrollment. IGC expects to complete enrollment by mid-2026, the primary operational gating step ahead of database lock and topline results.
GNA is internationally recognized for its long-running research into genetically linked Alzheimer’s disease and related neurodegenerative conditions, including longitudinal cohorts and biomarker’s research. For the Colombia site, Dr. Claudia Ramos, a psychiatrist at GNA with a PhD in Clinical Medicine, will serve as Principal Investigator and lead the project alongside a multidisciplinary team, including Sub-PI and General Coordinator of the GNA Dr. David Aguillón and an experienced group of neuropsychiatrists and medical researchers.
According to Ram Mukunda, CEO of IGC Pharma, GNA’s deep expertise in longitudinal Alzheimer’s cohorts and biomarkers provides IGC with a high caliber research environment that broadens access to participation and strengthens the diversity of their clinical program.
IGC also recognized the legacy of Dr. Francisco Lopera, founder of GNA and a globally respected Alzheimer’s researcher, who passed away in September 2024. Mukunda added that Dr. Lopera’s work elevated Alzheimer’s research across Latin America and helped reshape the field’s understanding of inherited Alzheimer’s. He said that IGC is honored to collaborate with the team Dr. Lopera built and inspired, and to advance Alzheimer’s research in Colombia with the scientific rigor he championed.
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s and metabolic disorders. The company’s lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer’s dementia. Its pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Source: IGC Pharma
